🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Catherine A. Shu

Columbia University Irving Medical Center

ORCID: 0000-0003-0765-7665
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile
1.0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

Cancer Discovery(2023)10.1158/2159-8290.cd-22-1020
Top 20%
1.0DataRank
Top 20%43 citations

Filemon S. Dela Cruz, Adina Grunn, Daniel Diolaiti, Audrey Mauguen, Allison R. Rainey +50 more

Papers

Driven by 9 papers — median percentile 80. Top paper: “A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies”.

A Transcriptome-Based Precision Oncology Platform for Patient–Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies

Cancer Discovery(2023)10.1158/2159-8290.cd-22-1020
Top 20%
1.0DataRank
Top 20%43 citations

Filemon S. Dela Cruz, Adina Grunn, Daniel Diolaiti, Audrey Mauguen, Allison R. Rainey +50 more

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Cancer Discovery(2023)10.1158/2159-8290.cd-22-1420
N/A
0.787DataRank · unranked
189 citations

Haniel A. Araújo, Giuseppe Lamberti, Alissa J. Cooper, Neal S. Akhave, Teng Zhou +61 more

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Nature(2024)10.1038/s41586-024-07943-7
N/A
0.769DataRank · unranked
168 citations

Haniel A. Araújo, Minh Truong, Yu Qian, Xin Sun, Ana Galán‐Cobo +95 more

Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.11.020
N/A
0.494DataRank · unranked
26 citations

Robyn Du, Nathaniel J. Myall, Whitney E. Lewis, Natalie Uy, Lingzhi Hong +22 more

Pre-clinical validation of an RNA-based precision oncology platform for patient-therapy alignment in a diverse set of human malignancies resistant to standard treatments

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.10.03.462951
N/A
0DataRank · unranked
7 citations

Filemon S. Dela Cruz, Adina Grunn, Daniel Diolaiti, Audrey Mauguen, Allison R. Rainey +48 more

The impact of eligibility criteria on Kirsten rat sarcoma G12C inhibitor trials in patients with non–small cell lung cancer

JNCI Journal of the National Cancer Institute(2025)10.1093/jnci/djaf236
N/A
0DataRank · unranked
4 citations

Michael May, Prashasti Agrawal, Jonathan Lee, Benjamin May, Xin Ma +11 more

Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy

Cancer Immunology Research(2022)10.1158/2326-6066.cir-22-0524
N/A
0DataRank · unranked
18 citations

Peter H. Wang, Robert S. Washburn, Radomir Kratchmarov, Shana M. Coley, Anjali Saqi +7 more

970TiP SKYSCRAPER-05: Phase II study of neoadjuvant atezolizumab (Atezo) + tiragolumab (Tira) with or without platinum-based chemotherapy (CT) in patients (Pts) with locally advanced resectable stage II‒IIIB NSCLC

Annals of Oncology(2022)10.1016/j.annonc.2022.07.1096
N/A
0DataRank · unranked
5 citations

A.W. Kim, Enriqueta Felip, Catherine A. Shu, Andrea Ferris, M. Frueh +8 more

Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC)

Journal of Clinical Oncology(2024)10.1200/jco.23.02668
N/A
0DataRank · unranked
49 citations

Emily Miao, Lillian A. Boe, Tejas Patil, Brandon S. Imber, Nathaniel J. Myall +19 more